Nanosized bioceramic particles could function as efficient gene delivery vehicles with target specificity for the spleen

We have compared the ability of several nanosized bioceramic particles including negatively charged silica (SiO 2 ), neutrally charged hydroxyapatite (HA) and positively charged zirconia (ZrO 2 ) nanoparticles as non-viral vectors for efficient in vivo gene delivery. A mixture of highly monodisperse...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gene therapy Jg. 14; H. 10; S. 828 - 835
Hauptverfasser: Tan, K, Cheang, P, Ho, I A W, Lam, P Y P, Hui, K M
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 01.05.2007
Nature Publishing Group
Schlagworte:
ISSN:0969-7128, 1476-5462
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract We have compared the ability of several nanosized bioceramic particles including negatively charged silica (SiO 2 ), neutrally charged hydroxyapatite (HA) and positively charged zirconia (ZrO 2 ) nanoparticles as non-viral vectors for efficient in vivo gene delivery. A mixture of highly monodispersed aqueous suspension of HA or SiO 2 nanoparticles, coated with protamine sulfate (PS), complexed efficiently with plasmid DNA and significantly enhanced transgene expression in vitro . In comparison, ZrO 2 nanoparticles gave poor transfection efficiency under similar conditions tested. It was also determined that, under the same conditions, PS-SiO 2 -DNA, but not PS-HA-DNA-nanoplexes, were able to mediate efficient transgene expression in vitro in the presence of 50% serum. Intraperitoneal injections of PS-SiO 2 -luciferase DNA nanoplexes targeted the highest level of transgene expression in the spleen of recipient mice that lasted for more than 48 h. Injection of PS-SiO 2 -pNGVL-hFLex-MUC-1 nanoplexes was able to mediate the production of Flt-3L in the sera of recipient mice. Simultaneously, the production of Flt-3L was accompanied by the stimulation of IL-2 and interferon- γ (IFN- γ ). Most importantly, the injection of PS-SiO 2 -pNGVL-hFLex-MUC-1 nanoplexes could mount potent anti-tumour specific immune responses that led to the subsequent regression of parental tumor cells containing the muc-1 determinant.
AbstractList We have compared the ability of several nanosized bioceramic particles including negatively charged silica (SiO sub(2)), neutrally charged hydroxyapatite (HA) and positively charged zirconia (ZrO sub(2)) nanoparticles as non-viral vectors for efficient in vivo gene delivery. A mixture of highly monodispersed aqueous suspension of HA or SiO sub(2) nanoparticles, coated with protamine sulfate (PS), complexed efficiently with plasmid DNA and significantly enhanced transgene expression in vitro. In comparison, ZrO sub(2) nanoparticles gave poor transfection efficiency under similar conditions tested. It was also determined that, under the same conditions, PS-SiO sub(2)-DNA, but not PS-HA-DNA-nanoplexes, were able to mediate efficient transgene expression in vitro in the presence of 50% serum. Intraperitoneal injections of PS-SiO sub(2)- luciferase DNA nanoplexes targeted the highest level of transgene expression in the spleen of recipient mice that lasted for more than 48 h. Injection of PS- SiO sub(2)-pNGVL-hFLex-MUC-1 nanoplexes was able to mediate the production of Flt- 3L in the sera of recipient mice. Simultaneously, the production of Flt-3L was accompanied by the stimulation of IL-2 and interferon-[gamma] (IFN- [gamma]). Most importantly, the injection of PS-SiO sub(2)-pNGVL-hFLex-MUC-1 nanoplexes could mount potent anti-tumour specific immune responses that led to the subsequent regression of parental tumor cells containing the muc-1 determinant.
We have compared the ability of several nanosized bioceramic particles including negatively charged silica (SiO(2)), neutrally charged hydroxyapatite (HA) and positively charged zirconia (ZrO(2)) nanoparticles as non-viral vectors for efficient in vivo gene delivery. A mixture of highly monodispersed aqueous suspension of HA or SiO(2) nanoparticles, coated with protamine sulfate (PS), complexed efficiently with plasmid DNA and significantly enhanced transgene expression in vitro. In comparison, ZrO(2) nanoparticles gave poor transfection efficiency under similar conditions tested. It was also determined that, under the same conditions, PS-SiO(2)-DNA, but not PS-HA-DNA-nanoplexes, were able to mediate efficient transgene expression in vitro in the presence of 50% serum. Intraperitoneal injections of PS-SiO(2)-luciferase DNA nanoplexes targeted the highest level of transgene expression in the spleen of recipient mice that lasted for more than 48 h. Injection of PS-SiO(2)-pNGVL-hFLex-MUC-1 nanoplexes was able to mediate the production of Flt-3L in the sera of recipient mice. Simultaneously, the production of Flt-3L was accompanied by the stimulation of IL-2 and interferon-gamma (IFN-gamma). Most importantly, the injection of PS-SiO(2)-pNGVL-hFLex-MUC-1 nanoplexes could mount potent anti-tumour specific immune responses that led to the subsequent regression of parental tumor cells containing the muc-1 determinant.
We have compared the ability of several nanosized bioceramic particles including negatively charged silica (SiO(2)), neutrally charged hydroxyapatite (HA) and positively charged zirconia (ZrO(2)) nanoparticles as non-viral vectors for efficient in vivo gene delivery. A mixture of highly monodispersed aqueous suspension of HA or SiO(2) nanoparticles, coated with protamine sulfate (PS), complexed efficiently with plasmid DNA and significantly enhanced transgene expression in vitro. In comparison, ZrO(2) nanoparticles gave poor transfection efficiency under similar conditions tested. It was also determined that, under the same conditions, PS-SiO(2)-DNA, but not PS-HA-DNA-nanoplexes, were able to mediate efficient transgene expression in vitro in the presence of 50% serum. Intraperitoneal injections of PS-SiO(2)-luciferase DNA nanoplexes targeted the highest level of transgene expression in the spleen of recipient mice that lasted for more than 48 h. Injection of PS-SiO(2)-pNGVL-hFLex-MUC-1 nanoplexes was able to mediate the production of Flt-3L in the sera of recipient mice. Simultaneously, the production of Flt-3L was accompanied by the stimulation of IL-2 and interferon-gamma (IFN-gamma). Most importantly, the injection of PS-SiO(2)-pNGVL-hFLex-MUC-1 nanoplexes could mount potent anti-tumour specific immune responses that led to the subsequent regression of parental tumor cells containing the muc-1 determinant.We have compared the ability of several nanosized bioceramic particles including negatively charged silica (SiO(2)), neutrally charged hydroxyapatite (HA) and positively charged zirconia (ZrO(2)) nanoparticles as non-viral vectors for efficient in vivo gene delivery. A mixture of highly monodispersed aqueous suspension of HA or SiO(2) nanoparticles, coated with protamine sulfate (PS), complexed efficiently with plasmid DNA and significantly enhanced transgene expression in vitro. In comparison, ZrO(2) nanoparticles gave poor transfection efficiency under similar conditions tested. It was also determined that, under the same conditions, PS-SiO(2)-DNA, but not PS-HA-DNA-nanoplexes, were able to mediate efficient transgene expression in vitro in the presence of 50% serum. Intraperitoneal injections of PS-SiO(2)-luciferase DNA nanoplexes targeted the highest level of transgene expression in the spleen of recipient mice that lasted for more than 48 h. Injection of PS-SiO(2)-pNGVL-hFLex-MUC-1 nanoplexes was able to mediate the production of Flt-3L in the sera of recipient mice. Simultaneously, the production of Flt-3L was accompanied by the stimulation of IL-2 and interferon-gamma (IFN-gamma). Most importantly, the injection of PS-SiO(2)-pNGVL-hFLex-MUC-1 nanoplexes could mount potent anti-tumour specific immune responses that led to the subsequent regression of parental tumor cells containing the muc-1 determinant.
We have compared the ability of several nanosized bioceramic particles including negatively charged silica (SiO 2 ), neutrally charged hydroxyapatite (HA) and positively charged zirconia (ZrO 2 ) nanoparticles as non-viral vectors for efficient in vivo gene delivery. A mixture of highly monodispersed aqueous suspension of HA or SiO 2 nanoparticles, coated with protamine sulfate (PS), complexed efficiently with plasmid DNA and significantly enhanced transgene expression in vitro . In comparison, ZrO 2 nanoparticles gave poor transfection efficiency under similar conditions tested. It was also determined that, under the same conditions, PS-SiO 2 -DNA, but not PS-HA-DNA-nanoplexes, were able to mediate efficient transgene expression in vitro in the presence of 50% serum. Intraperitoneal injections of PS-SiO 2 -luciferase DNA nanoplexes targeted the highest level of transgene expression in the spleen of recipient mice that lasted for more than 48 h. Injection of PS-SiO 2 -pNGVL-hFLex-MUC-1 nanoplexes was able to mediate the production of Flt-3L in the sera of recipient mice. Simultaneously, the production of Flt-3L was accompanied by the stimulation of IL-2 and interferon- γ (IFN- γ ). Most importantly, the injection of PS-SiO 2 -pNGVL-hFLex-MUC-1 nanoplexes could mount potent anti-tumour specific immune responses that led to the subsequent regression of parental tumor cells containing the muc-1 determinant.
We have compared the ability of several nanosized bioceramic particles including negatively charged silica (SiO2), neutrally charged hydroxyapatite (HA) and positively charged zirconia (ZrO2) nanoparticles as non-viral vectors for efficient in vivo gene delivery. A mixture of highly monodispersed aqueous suspension of HA or SiO2 nanoparticles, coated with protamine sulfate (PS), complexed efficiently with plasmid DNA and significantly enhanced transgene expression in vitro. In comparison, ZrO2 nanoparticles gave poor transfection efficiency under similar conditions tested. It was also determined that, under the same conditions, PS-SiO2-DNA, but not PS-HA-DNA-nanoplexes, were able to mediate efficient transgene expression in vitro in the presence of 50% serum. Intraperitoneal injections of PS-SiO2-luciferase DNA nanoplexes targeted the highest level of transgene expression in the spleen of recipient mice that lasted for more than 48 h. Injection of PS-SiO2-pNGVL-hFLex-MUC-1 nanoplexes was able to mediate the production of Flt-3L in the sera of recipient mice. Simultaneously, the production of Flt-3L was accompanied by the stimulation of IL-2 and interferon-γ (IFN-γ). Most importantly, the injection of PS-SiO2-pNGVL-hFLex-MUC-1 nanoplexes could mount potent anti-tumour specific immune responses that led to the subsequent regression of parental tumor cells containing the muc-1 determinant.
Audience Academic
Author Ho, I A W
Lam, P Y P
Tan, K
Cheang, P
Hui, K M
Author_xml – sequence: 1
  givenname: K
  surname: Tan
  fullname: Tan, K
  organization: School of Chemical and Biomedical Engineering, Nanyang Technological University
– sequence: 2
  givenname: P
  surname: Cheang
  fullname: Cheang, P
  organization: School of Chemical and Biomedical Engineering, Nanyang Technological University
– sequence: 3
  givenname: I A W
  surname: Ho
  fullname: Ho, I A W
  organization: Division of Cellular & Molecular Research, National Cancer Centre
– sequence: 4
  givenname: P Y P
  surname: Lam
  fullname: Lam, P Y P
  organization: Division of Cellular & Molecular Research, National Cancer Centre
– sequence: 5
  givenname: K M
  surname: Hui
  fullname: Hui, K M
  email: cmrhkm@nccs.com.sg
  organization: School of Chemical and Biomedical Engineering, Nanyang Technological University, Division of Cellular & Molecular Research, National Cancer Centre
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18725022$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/17344903$$D View this record in MEDLINE/PubMed
BookMark eNqFkstrGzEQxkVJaRy3x16LaGigh3UlrbSPYwh9BEILfZyFVju7lllLrqRN4_711WIX1yGhSCA0_L6Z0eg7QyfWWUDoJSULSvLqXVgt-rjIc8LqvHyCZpSXRSZ4wU7QjNRFnZWUVafoLIQVIYSXFXuGTmmZc16TfIbuPivrgvkNLW6M0-DV2mi8UT4aPUDA2o1Di7vR6micxSpg6DqjDdiIe7CAWxjMLfgtvoXlTvLLxCWOyvcQcdiANhMft7hzHsclpNgAYJ-jp50aArzYn3P048P771efspsvH6-vLm8yLcoqZqJljaBQp96LXJR5WqLOheJNJxpF66pNIaqZFkQxpViuaSugpR1wTZp0n6OLXd6Ndz9HCFGuTdAwDMqCG4MsCS9qVov_gqmW4KSYMp7fA1du9DY9QrKC8yI1lPYcvX6UolVJOSfikKpXA0hjOxe90lNdeUkrxipS1VWiFg9QabWQPivZoTMpfiR4eyRITIS72KsxBHn97esxe_EPuwQ1xGVwwzh9dzgGX-0fNDZraOXGm7XyW_nXSwl4swdU0GrovLLahANXlUwQNs0v23HauxA8dAeEyMnTMqxkH-Xe04nP7_HJTmrqL43BDI-q9kMLKbvtwR_m_7DgDxs1Bqg
CitedBy_id crossref_primary_10_1002_app_34140
crossref_primary_10_1088_0957_4484_22_10_105708
crossref_primary_10_1016_j_ceramint_2021_07_100
crossref_primary_10_1002_adhm_201901695
crossref_primary_10_18502_ijrm_v13i9_7671
crossref_primary_10_1007_s11051_011_0708_1
crossref_primary_10_3892_etm_2019_7158
crossref_primary_10_1016_j_bioactmat_2021_01_020
crossref_primary_10_1016_j_jconrel_2019_09_009
crossref_primary_10_1039_c2jm31109g
crossref_primary_10_1515_ejnm_2015_0015
crossref_primary_10_1002_jssc_201700028
crossref_primary_10_1002_bit_23041
crossref_primary_10_1021_acs_chemrev_7b00258
crossref_primary_10_1159_000453446
crossref_primary_10_3390_biophysica4010006
crossref_primary_10_3892_mmr_2017_6583
crossref_primary_10_1016_j_biomaterials_2012_10_001
crossref_primary_10_4028_www_scientific_net_KEM_441_307
crossref_primary_10_1016_j_actbio_2011_06_018
crossref_primary_10_1186_1556_276X_6_600
crossref_primary_10_1002_cbic_200900341
crossref_primary_10_1002_chem_201705723
crossref_primary_10_2217_fon_12_171
crossref_primary_10_1016_j_aca_2009_05_037
crossref_primary_10_1016_j_nano_2009_05_003
crossref_primary_10_1007_s11051_011_0353_8
crossref_primary_10_1007_s11051_015_3316_7
crossref_primary_10_1016_S1003_6326_11_60929_1
crossref_primary_10_2147_IJN_S360670
Cites_doi 10.1002/jcb.20796
10.1016/j.jconrel.2003.11.019
10.1038/nri1669
10.1038/sj.gt.3302365
10.1016/S0065-2660(05)53003-7
10.1016/S0142-9612(03)00066-8
10.1211/002235703765951311
10.1038/sj.gt.3302639
10.1038/sj.gt.3301923
10.1038/nbt843
10.1038/nrg1577
10.1038/sj.gt.3301783
10.1016/S0049-3848(98)00201-1
10.1016/S0065-2660(05)53002-5
10.1016/j.biopha.2004.01.003
10.4049/jimmunol.174.5.2612
10.1038/nrd1960
10.1021/la049304f
10.1038/nrg1829
10.1038/sj.gt.3301759
10.1038/sj.gt.3301914
10.1016/j.ymthe.2006.03.026
10.1124/pr.58.1.8
10.1096/fj.05-5411fje
ContentType Journal Article
Copyright Springer Nature Limited 2007
2007 INIST-CNRS
COPYRIGHT 2007 Nature Publishing Group
Copyright Nature Publishing Group May 2007
Nature Publishing Group 2007.
Copyright_xml – notice: Springer Nature Limited 2007
– notice: 2007 INIST-CNRS
– notice: COPYRIGHT 2007 Nature Publishing Group
– notice: Copyright Nature Publishing Group May 2007
– notice: Nature Publishing Group 2007.
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
ISR
3V.
7QP
7TK
7TM
7U9
7X7
7XB
88E
8AO
8C1
8FD
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K9.
LK8
M0S
M1P
M2O
M7P
MBDVC
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
RC3
7QO
7X8
DOI 10.1038/sj.gt.3302937
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials Local Electronic Collection Information
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
Research Library
Biological Science Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
Genetics Abstracts
Biotechnology Research Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
ProQuest One Applied & Life Sciences
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Public Health
ProQuest Central Basic
ProQuest SciTech Collection
ProQuest Medical Library
ProQuest Central (Alumni)
Biotechnology Research Abstracts
MEDLINE - Academic
DatabaseTitleList Genetics Abstracts
MEDLINE
MEDLINE - Academic
Research Library Prep

Research Library Prep
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1476-5462
EndPage 835
ExternalDocumentID 1267758271
A182280898
17344903
18725022
10_1038_sj_gt_3302937
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Singapore
GeographicLocations_xml – name: Singapore
GroupedDBID ---
-Q-
.55
.GJ
0R~
29H
2WC
36B
39C
3V.
4.4
406
53G
5GY
70F
7X7
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8R4
8R5
AACDK
AANZL
AASML
AATNV
AAYZH
AAZLF
ABAKF
ABAWZ
ABDBF
ABJNI
ABLJU
ABUWG
ABZZP
ACAOD
ACGFS
ACKTT
ACMJI
ACPRK
ACRQY
ACUHS
ACZOJ
ADBBV
ADFRT
ADHDB
AEFQL
AEJRE
AEMSY
AENEX
AEVLU
AEXYK
AFBBN
AFKRA
AFSHS
AGAYW
AGHAI
AGQEE
AHMBA
AHSBF
AIGIU
AILAN
AJRNO
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMYLF
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B0M
BAWUL
BBNVY
BENPR
BHPHI
BKKNO
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
DIK
DNIVK
DPUIP
DU5
DWQXO
E3Z
EAD
EAP
EBC
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
FDQFY
FEDTE
FERAY
FIGPU
FIZPM
FSGXE
FYUFA
GNUQQ
GUQSH
HCIFZ
HMCUK
HVGLF
HZ~
IAO
IEA
IGG
IHR
IHW
INH
INR
ISR
ITC
IWAJR
JSO
JZLTJ
KQ8
LK8
M1P
M2O
M7P
N9A
NAO
NQJWS
O9-
OK1
OVD
PQQKQ
PROAC
PSQYO
Q2X
RNS
RNT
RNTTT
ROL
SNX
SNYQT
SOHCF
SOJ
SRMVM
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TEORI
TR2
TSG
TUS
UDS
UKHRP
W2D
X7M
Y6R
~8M
AAYXX
ABBRH
ABDBE
ABFSG
ABRTQ
ACSTC
AEZWR
AFDZB
AFFHD
AFHIU
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
IQODW
NXXTH
CGR
CUY
CVF
ECM
EIF
NPM
ACMFV
7QP
7TK
7TM
7U9
7XB
8FD
8FK
FR3
H94
K9.
MBDVC
P64
PKEHL
PQEST
PQUKI
PRINS
Q9U
RC3
7QO
7X8
PUEGO
ID FETCH-LOGICAL-c578t-5d2b51e9000635737375935a4bf5ba198d3731c2c50a2aa23c1d5ed1fe4c0ba23
IEDL.DBID M7P
ISICitedReferencesCount 51
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000246210900005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0969-7128
IngestDate Wed Oct 01 14:46:34 EDT 2025
Tue Oct 07 08:05:12 EDT 2025
Mon Oct 06 17:40:44 EDT 2025
Fri Oct 03 11:01:25 EDT 2025
Sat Nov 29 14:10:53 EST 2025
Sat Nov 29 10:53:15 EST 2025
Wed Nov 26 10:59:38 EST 2025
Thu May 22 21:08:54 EDT 2025
Wed Feb 12 01:04:27 EST 2025
Mon Jul 21 09:15:56 EDT 2025
Sat Nov 29 01:48:45 EST 2025
Tue Nov 18 22:18:34 EST 2025
Fri Feb 21 02:38:03 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords tumor-specific immune responses
nanoplexes
spleen
nano-bioceramics particles
silica
non-viral vector
Particle
Spleen
Specificity
Immune response
Tumor
Gene therapy
Vector
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c578t-5d2b51e9000635737375935a4bf5ba198d3731c2c50a2aa23c1d5ed1fe4c0ba23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 17344903
PQID 218714405
PQPubID 34384
PageCount 8
ParticipantIDs proquest_miscellaneous_70469295
proquest_miscellaneous_19854062
proquest_journals_2644637337
proquest_journals_218714405
gale_infotracmisc_A182280898
gale_infotracacademiconefile_A182280898
gale_incontextgauss_ISR_A182280898
gale_healthsolutions_A182280898
pubmed_primary_17344903
pascalfrancis_primary_18725022
crossref_primary_10_1038_sj_gt_3302937
crossref_citationtrail_10_1038_sj_gt_3302937
springer_journals_10_1038_sj_gt_3302937
PublicationCentury 2000
PublicationDate 2007-05-01
PublicationDateYYYYMMDD 2007-05-01
PublicationDate_xml – month: 05
  year: 2007
  text: 2007-05-01
  day: 01
PublicationDecade 2000
PublicationPlace London
PublicationPlace_xml – name: London
– name: Basingstoke
– name: England
– name: Houndmills
PublicationTitle Gene therapy
PublicationTitleAbbrev Gene Ther
PublicationTitleAlternate Gene Ther
PublicationYear 2007
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References C Lawson (BF3302937_CR4) 2006; 333
TP O'Connor (BF3302937_CR22) 2006; 7
YW Cho (BF3302937_CR23) 2003; 55
ML Read (BF3302937_CR18) 2005; 53
IA Khalil (BF3302937_CR8) 2006; 58
E Mastrobattista (BF3302937_CR10) 2006; 5
SJ Hwang (BF3302937_CR24) 2001; 3
TC Yih (BF3302937_CR14) 2006; 97
Y Tan (BF3302937_CR25) 2002; 69
Y Morita (BF3302937_CR13) 2004; 14
E Tupin (BF3302937_CR27) 2003; 10
Y Wang (BF3302937_CR2) 2006; 34
DJ Glover (BF3302937_CR5) 2005; 6
Y Byun (BF3302937_CR26) 1999; 94
E Wagner (BF3302937_CR1) 2004; 58
SS Larin (BF3302937_CR6) 2004; 11
RE Mebius (BF3302937_CR19) 2005; 5
CL Fong (BF3302937_CR21) 2006; 13
VG Pillarisetty (BF3302937_CR28) 2005; 174
M Nishikawa (BF3302937_CR17) 2005; 53
E Dauty (BF3302937_CR11) 2002; 9
R Kumar (BF3302937_CR16) 2004; 20
CL Fong (BF3302937_CR20) 2002; 9
UI Chaudhry (BF3302937_CR29) 2006; 20
T Niidome (BF3302937_CR3) 2002; 9
D Luo (BF3302937_CR12) 2004; 95
DA Jackson (BF3302937_CR7) 2006; 14
T Yamada (BF3302937_CR9) 2003; 21
R Kumar (BF3302937_CR15) 2003; 24
References_xml – volume: 97
  start-page: 1184
  year: 2006
  ident: BF3302937_CR14
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.20796
– volume: 95
  start-page: 333
  year: 2004
  ident: BF3302937_CR12
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2003.11.019
– volume: 5
  start-page: 606
  year: 2005
  ident: BF3302937_CR19
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri1669
– volume: 69
  start-page: 73
  year: 2002
  ident: BF3302937_CR25
  publication-title: Methods Mol Med
– volume: 11
  start-page: S18
  issue: Suppl 1
  year: 2004
  ident: BF3302937_CR6
  publication-title: Gene Ther
  doi: 10.1038/sj.gt.3302365
– volume: 333
  start-page: 175
  year: 2006
  ident: BF3302937_CR4
  publication-title: Methods Mol Biol
– volume: 53
  start-page: 47
  year: 2005
  ident: BF3302937_CR17
  publication-title: Adv Genet
  doi: 10.1016/S0065-2660(05)53003-7
– volume: 24
  start-page: 2611
  year: 2003
  ident: BF3302937_CR15
  publication-title: Biomaterials
  doi: 10.1016/S0142-9612(03)00066-8
– volume: 55
  start-page: 721
  year: 2003
  ident: BF3302937_CR23
  publication-title: J Pharm Pharmacol
  doi: 10.1211/002235703765951311
– volume: 13
  start-page: 245
  year: 2006
  ident: BF3302937_CR21
  publication-title: Gene Ther
  doi: 10.1038/sj.gt.3302639
– volume: 9
  start-page: 1647
  year: 2002
  ident: BF3302937_CR3
  publication-title: Gene Ther
  doi: 10.1038/sj.gt.3301923
– volume: 21
  start-page: 885
  year: 2003
  ident: BF3302937_CR9
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt843
– volume: 6
  start-page: 299
  year: 2005
  ident: BF3302937_CR5
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg1577
– volume: 9
  start-page: 1127
  year: 2002
  ident: BF3302937_CR20
  publication-title: Gene Ther
  doi: 10.1038/sj.gt.3301783
– volume: 94
  start-page: 53
  year: 1999
  ident: BF3302937_CR26
  publication-title: Thromb Res
  doi: 10.1016/S0049-3848(98)00201-1
– volume: 3
  start-page: 183
  year: 2001
  ident: BF3302937_CR24
  publication-title: Curr Opin Mol Ther
– volume: 34
  start-page: 114
  year: 2006
  ident: BF3302937_CR2
  publication-title: Biomed Eng
– volume: 14
  start-page: 263
  year: 2004
  ident: BF3302937_CR13
  publication-title: Biomed Mater Eng
– volume: 53
  start-page: 19
  year: 2005
  ident: BF3302937_CR18
  publication-title: Adv Genet
  doi: 10.1016/S0065-2660(05)53002-5
– volume: 58
  start-page: 152
  year: 2004
  ident: BF3302937_CR1
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2004.01.003
– volume: 174
  start-page: 2612
  year: 2005
  ident: BF3302937_CR28
  publication-title: J Immunol
  doi: 10.4049/jimmunol.174.5.2612
– volume: 5
  start-page: 115
  year: 2006
  ident: BF3302937_CR10
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd1960
– volume: 20
  start-page: 5196
  year: 2004
  ident: BF3302937_CR16
  publication-title: Langmuir
  doi: 10.1021/la049304f
– volume: 7
  start-page: 261
  year: 2006
  ident: BF3302937_CR22
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg1829
– volume: 9
  start-page: 743
  year: 2002
  ident: BF3302937_CR11
  publication-title: Gene Ther
  doi: 10.1038/sj.gt.3301759
– volume: 10
  start-page: 569
  year: 2003
  ident: BF3302937_CR27
  publication-title: Gene Ther
  doi: 10.1038/sj.gt.3301914
– volume: 14
  start-page: 613
  year: 2006
  ident: BF3302937_CR7
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2006.03.026
– volume: 58
  start-page: 32
  year: 2006
  ident: BF3302937_CR8
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.58.1.8
– volume: 20
  start-page: 982
  year: 2006
  ident: BF3302937_CR29
  publication-title: FASEB J
  doi: 10.1096/fj.05-5411fje
SSID ssj0004782
Score 2.099999
Snippet We have compared the ability of several nanosized bioceramic particles including negatively charged silica (SiO 2 ), neutrally charged hydroxyapatite (HA) and...
We have compared the ability of several nanosized bioceramic particles including negatively charged silica (SiO(2)), neutrally charged hydroxyapatite (HA) and...
We have compared the ability of several nanosized bioceramic particles including negatively charged silica (SiO2), neutrally charged hydroxyapatite (HA) and...
We have compared the ability of several nanosized bioceramic particles including negatively charged silica (SiO sub(2)), neutrally charged hydroxyapatite (HA)...
SourceID proquest
gale
pubmed
pascalfrancis
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 828
SubjectTerms Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Animals
Applied cell therapy and gene therapy
Biocompatible Materials
Biological and medical sciences
Biological assay
Biomedical and Life Sciences
Biomedicine
Biotechnology
Cell Biology
Cell Line, Tumor
Ceramics in medicine
Deoxyribonucleic acid
DNA
Female
Fundamental and applied biological sciences. Psychology
Gene Expression
Gene Therapy
Gene transfer
Genetic Therapy - methods
Health aspects
Health. Pharmaceutical industry
Human Genetics
Humans
Hydroxyapatite
Immune response
Industrial applications and implications. Economical aspects
Injection
Interferon-gamma - blood
Interleukin 2
Interleukin-2 - blood
Liposomes
Luciferases - genetics
Medical sciences
Melanoma, Experimental
Membrane Proteins - blood
Methods
Mice
Mice, Inbred BALB C
Microscopy, Confocal
Microscopy, Electron
Nanoparticles
Nanotechnology
Neoplasms - immunology
Neoplasms - metabolism
Neoplasms - therapy
original-article
Protamine sulfate
Silicon dioxide
Spleen
Spleen - metabolism
Transfection
Transfection - methods
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Tumor cells
Zirconia
γ-Interferon
Title Nanosized bioceramic particles could function as efficient gene delivery vehicles with target specificity for the spleen
URI https://link.springer.com/article/10.1038/sj.gt.3302937
https://www.ncbi.nlm.nih.gov/pubmed/17344903
https://www.proquest.com/docview/218714405
https://www.proquest.com/docview/2644637337
https://www.proquest.com/docview/19854062
https://www.proquest.com/docview/70469295
Volume 14
WOSCitedRecordID wos000246210900005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 1476-5462
  dateEnd: 20171231
  omitProxy: false
  ssIdentifier: ssj0004782
  issn: 0969-7128
  databaseCode: M7P
  dateStart: 19970201
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1476-5462
  dateEnd: 20171231
  omitProxy: false
  ssIdentifier: ssj0004782
  issn: 0969-7128
  databaseCode: BENPR
  dateStart: 19970201
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Health & Medical Complete
  customDbUrl:
  eissn: 1476-5462
  dateEnd: 20171231
  omitProxy: false
  ssIdentifier: ssj0004782
  issn: 0969-7128
  databaseCode: 7X7
  dateStart: 19970201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Research Library
  customDbUrl:
  eissn: 1476-5462
  dateEnd: 20171231
  omitProxy: false
  ssIdentifier: ssj0004782
  issn: 0969-7128
  databaseCode: M2O
  dateStart: 19970201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/pqrl
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database (subscription)
  customDbUrl:
  eissn: 1476-5462
  dateEnd: 20171231
  omitProxy: false
  ssIdentifier: ssj0004782
  issn: 0969-7128
  databaseCode: 8C1
  dateStart: 19970201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfYhhAS4vujbBQLIXhZtsROYvsJjWkTSKxUA6S-WY7jlE5TW-p2Av567hK3VUTHCy-REl_rjzvf_Wyf7wh5bauM5zxPIpkaWKAktopMwmxUOg5wXuRF3ARJ-iR6PTkYqH7YcPPBrXKpE2tFXU4s7pEfouHOueBcvJv-iDBrFJ6uhhQaW2QHoySw2nWvv74XKepkUYDSVSRAEYcYmzGXh_7iYDg_gMU8mDvRsklBM9-ZGg-jVDXpLTbhz7_OTmuTdHrvfztzn9wNYJQeNdLzgNxw44fk1lk4bn9EfoLunfjRb1fSYgSGbobJ6-l06UxHLebHpmgakb3UeOrqiBRgyCgIpqOlu0S_j1_0yn1vfoL7vrRxP6d4yxM9lWAhQAE7U8Ci8A19Ox6Tb6cnX48_RCFVQ2Rhys-jrGRFljhVQ55MQNdEpnhm0qLKCpMoWcKnxDKbxYYZw7hNysyVSeVSGxfw_oRsjydj94xQlbhMCFcBcCjSsrKKlU5Zw3llbAxwqUP2l8zSNsQxx3Qal7o-T-dS-ws9nOvA2w55syKfNgE8riN8iZzXzf3T1cTXR7ACYzKWSnbIq5oCw2aM0S9naBbe649fzltEbwNRNYFmWROuOUDnMNJWi3KvRQnz2raKuy0RXLdeCsCtjHXI7lK4dFA8XgNiE3hen8G_byhdyR30dlWMFaOr3dhNFl4DswDF5-x6CoF7KkxBFU-bmbBumuBpqmIOg7CcGuvKN4768383c5fcbjbT0cN0j2zPZwv3gty0V_ORn3XJlhiI-inhKY-TLtl5f9Lrn8PbGfvcrbXBH1IpYkY
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamgQAJcb-Ujc1CXF7IlthxnTwgNAHTqnUFwZD2ZhzHKZ1GWup0MH4Uv5FzcmkV0fG2B17jE1-Pz8X-fA4hT00meJd3Ay8KNTgogck8HTDjpZaDOS-7iV8FSerLwSA6Ooo_rJDfzVsYhFU2MrEU1OnY4Bn5NiruLpecy9eT7x5mjcLb1SaFRsUW-_bsB7hs7lXvLazvM8Z23x2-2fPqrAKeAe4sPJGyRAQ2LrWzkFClFDEXOkwykWjwwVP4FBhmhK-Z1oybIBU2DTIbGj_RGOgARP6lED0hhAqy94t3mLJMTgVeQexJEPx1TE-fR9vueGtYbHHug3qVLR1Ya4LrE-1gVbIqncYye_evu9pSBe7e_N8m7xa5URvbdKfaHbfJis3vkCsHNZzgLvkJumXsRr9sSpMRKPKp_jYydNKABanB_N8UVT-yL9WO2jLiBihqChvP0tSeIK7ljJ7ar9UveK5NK3g9xVesiMQCR4eCb0DB1oZviF25Rz5fyLjvk9V8nNuHhMaBFVLaDAyjJEwzE7PUxkZznmnjgznYIS8b5lCmjtOO6UJOVIkX4JFyx2pYqJqXOuT5nHxSBSg5j3ATOU1V72vngk3tgIfJIj-Kow55UlJgWJAccUdDPXNO9T59bBG9qImyMXTL6PoZBwwOI4m1KNdblCC3TKt4o8Xyi95HEuxyxjpkrWFmVQtWp8AilYhHEFD7ktI5n8No58XYMEIJczueOQWLBV5Kl51PIfHMiMXQxINq5y26JnkYxj6HSWi24qLxpbP-6N_d3CRX9w4P-qrfG-yvkWvVxQGiadfJajGd2cfksjktRm66UUoaSr5c9O78AyC8uMY
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamDk1IiPulbGwW4vJC1sSO6-QBocFWUW1U1QBpb8ZxnNJptKVpB-On8es4J3FaRXS87YHX-CTx5Vztz-cQ8sxkgrd5O_CiUEOAEpjM0wEzXmo5uPOynfhlkqQj2etFJydxf438ru7CIKyy0omFok7HBvfIW2i421xyLluZg0X09ztvJt89rCCFJ61VOY2SRQ7txQ8I3_LX3X1Y6-eMdQ4-vXvvuQoDngFOnXkiZYkIbFxYaiHh81LEXOgwyUSiIR5P4VFgmBG-ZlozboJU2DTIbGj8RGPSA1D_6xKcjLBB1t8e9PrHy1uZsihVBTFC7EkwAy7Dp8-jVn66O5jtcu6DsZU1i-jswo2JzmGNsrK4xirv96-T28Igdm79z1N5m9x0bjjdK-XmDlmzo7tk44MDGtwjP8HqjPPhL5vSZAgmfqq_DQ2dVDBCarAyOEWnABmb6pzaIhcHmHAKImlpas8Q8XJBz-3X8hXc8aYl8J7i_VbEaEEIRCFqoOCFwzNEtdwnn69k3A9IYzQe2UeExoEVUtoMXKYkTDMTs9TGRnOeaeODo9gkrypGUcZlcMdCImeqQBLwSOWnajBTjq-a5MWCfFKmLrmMcAe5TpU3bxcqT-1B7MkiP4qjJnlaUGDCkBHyy0DP81x1Px7XiF46omwM3TLaXfCAwWGOsRrlVo0SNJqpNW_X2H_Z-0iCx85Yk2xWjK2cys0V-KoSkQoCvr6idcHzMNpFM_4YQYYjO57nChYL4pc2u5xC4m4Si-EXD0spXHZN8jCMfQ6TUInl8ucrZ_3xv7u5QzZAKNVRt3e4Sa6XJwoIs90ijdl0bp-Qa-Z8Nsyn207tUPLlqsXzDzWxwuM
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nanosized+bioceramic+particles+could+function+as+efficient+gene+delivery+vehicles+with+target+specificity+for+the+spleen&rft.jtitle=Gene+therapy&rft.au=Tan%2C+K&rft.au=Cheang%2C+P&rft.au=Ho%2C+I+A+W&rft.au=Lam%2C+P+Y+P&rft.date=2007-05-01&rft.pub=Nature+Publishing+Group+UK&rft.issn=0969-7128&rft.eissn=1476-5462&rft.volume=14&rft.issue=10&rft.spage=828&rft.epage=835&rft_id=info:doi/10.1038%2Fsj.gt.3302937&rft.externalDocID=10_1038_sj_gt_3302937
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0969-7128&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0969-7128&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0969-7128&client=summon